MSCs |
• self-renewal ability |
(36, 40−43) |
|
• multipotent |
|
|
• ease of access |
|
|
• efficient in
vitro expansion |
|
|
• free of ethical concerns |
|
|
• nonsignificant immune
responses |
|
|
• variable therapeutic
results depending on the source and the donor |
|
ESCs |
• pluripotent |
(42, 44−48) |
|
• ethical concerns |
|
|
• possible tumor formation
during the differentiation |
|
|
• possible immune
rejection
after transplantation |
|
|
• possible cell heterogeneity |
|
iPSCs |
• pluripotent |
(41, 42, 47−50) |
|
• free of ethical concerns |
|
|
• possible tumor formation
during the differentiation |
|
|
• possible immune
rejection
after transplantation |
|
|
• possible cell heterogeneity |
|
NSCs |
• multipotent |
(42, 47, 50−52) |
|
• efficient in
vitro expansion |
|
|
• secretion of neurotrophic
factors |
|
|
• less potential of forming
tumors compared with ESCs |
|
Schwann cells |
• production of growth
factors, cell adhesion molecules, and extracellular matrix proteins |
(41, 47) |
|
• myelinating function |
|
|
• support of axonal regeneration |
|
|
• efficacy and safety |
|